Spyre Therapeutics, Inc. SYRE Common Stock, Shares, Outstanding
Common Stock, Shares, Outstanding at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesOutstanding.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s common stock, shares, outstanding.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s common stock, shares, outstanding?
- Spyre Therapeutics, Inc. (SYRE) reported common stock, shares, outstanding of $78.84M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s common stock, shares, outstanding changed year-over-year?
- Spyre Therapeutics, Inc.'s common stock, shares, outstanding increased by 30.8% year-over-year, from $60.28M to $78.84M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s common stock, shares, outstanding?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s common stock, shares, outstanding has grown at a 210.4% compound annual growth rate (CAGR), from $2.61M to $78.19M.